JP2024525078A5 - - Google Patents

Info

Publication number
JP2024525078A5
JP2024525078A5 JP2024500173A JP2024500173A JP2024525078A5 JP 2024525078 A5 JP2024525078 A5 JP 2024525078A5 JP 2024500173 A JP2024500173 A JP 2024500173A JP 2024500173 A JP2024500173 A JP 2024500173A JP 2024525078 A5 JP2024525078 A5 JP 2024525078A5
Authority
JP
Japan
Prior art keywords
rnai
sense strand
antisense strand
strand
acetylgalactosamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024500173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525078A (ja
JP7853399B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2022/009984 external-priority patent/WO2023282704A1/ko
Publication of JP2024525078A publication Critical patent/JP2024525078A/ja
Publication of JP2024525078A5 publication Critical patent/JP2024525078A5/ja
Priority to JP2026067672A priority Critical patent/JP2026120732A/ja
Application granted granted Critical
Publication of JP7853399B2 publication Critical patent/JP7853399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024500173A 2021-07-08 2022-07-08 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途 Active JP7853399B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026067672A JP2026120732A (ja) 2021-07-08 2026-04-16 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2021-0089864 2021-07-08
KR20210089864 2021-07-08
PCT/KR2022/009984 WO2023282704A1 (ko) 2021-07-08 2022-07-08 Marc1 유전자를 표적으로 하는 rnai 제제 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026067672A Division JP2026120732A (ja) 2021-07-08 2026-04-16 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途

Publications (3)

Publication Number Publication Date
JP2024525078A JP2024525078A (ja) 2024-07-09
JP2024525078A5 true JP2024525078A5 (enExample) 2026-01-20
JP7853399B2 JP7853399B2 (ja) 2026-04-28

Family

ID=84801791

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024500173A Active JP7853399B2 (ja) 2021-07-08 2022-07-08 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途
JP2026067672A Pending JP2026120732A (ja) 2021-07-08 2026-04-16 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026067672A Pending JP2026120732A (ja) 2021-07-08 2026-04-16 ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途

Country Status (8)

Country Link
US (1) US20250179498A1 (enExample)
EP (1) EP4368717A4 (enExample)
JP (2) JP7853399B2 (enExample)
KR (1) KR20230010593A (enExample)
CN (1) CN117677697A (enExample)
AU (1) AU2022308807B2 (enExample)
CA (1) CA3225054A1 (enExample)
WO (1) WO2023282704A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024186171A1 (ko) * 2023-03-08 2024-09-12 올릭스 주식회사 비만의 예방 또는 치료용 RNAi 제제 및 이를 이용한 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090905A1 (es) * 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
TWI664187B (zh) * 2013-05-22 2019-07-01 阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
CN110799192A (zh) * 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
US10835581B2 (en) * 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
SG11202105900UA (en) * 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
US20200241005A1 (en) * 2019-01-25 2020-07-30 Viscient Biosciences, Inc. Compositions and methods for the diagnosis and treatment of diseases of the liver
US12215382B2 (en) * 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2021237097A1 (en) * 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
EP4196584A2 (en) * 2020-08-13 2023-06-21 Amgen Inc. Rnai constructs and methods for inhibiting marc1 expression
US11655473B2 (en) * 2021-05-28 2023-05-23 Novo Nordisk A/S Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression

Similar Documents

Publication Publication Date Title
CN106255755B (zh) 用于调节血管生成素样蛋白3表达的组合物和方法
TW202323524A (zh) Ｈｂｂ—調節組合物及方法
JP2025019119A (ja) ケイ素を含有するカチオン性脂質
TW202024324A (zh) 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法
PT2015758E (pt) Compostos e métodos para modular a expressão da proteína apob
JP6396891B2 (ja) 遺伝子改変コクサッキーウイルス
JP2016520312A5 (enExample)
JP2017509354A5 (enExample)
CN115397436A (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
JP2016523548A (ja) 成長ホルモン受容体のモジュレータ
CA3147643A1 (en) Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
CN117295819A (zh) 用于抑制补体组分3表达的组合物和方法
CN121866332A (zh) 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
JP2023533124A (ja) 二本鎖オリゴヌクレオチド及びこれを含むコロナウイルス感染症－１９（ｃｏｖｉｄ－１９）治療用組成物
JP7106788B2 (ja) Ｍｅｘ３ｂ遺伝子の発現を抑制する核酸、ｍｅｘ３ｂ遺伝子発現抑制剤、ｍｅｘ３ｂ遺伝子発現を抑制する方法及びｍｅｘ３ｂ遺伝子発現に起因する疾病の予防又は治療剤
WO2025201416A1 (zh) 靶向抑制素亚单位βE的核酸及其用途
JP2024506882A (ja) 化学修飾された低分子活性化ｒｎａ
TW201119681A (en) Compositions and methods for inhibiting expression of KIF10 genes
JP2022064910A (ja) 副腎脊髄ニューロパチーの治療のためのａｂｃｄ１をコードする核酸配列の髄腔内送達
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
JP7853399B2 (ja) ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法
WO2016077704A1 (en) Modulation of agpat5 expression
JP2024529930A5 (enExample)
WO2022270071A1 (ja) 肝線維化抑制のための剤及び医薬組成物